INSPIROGENE
Live / Allowed — Notice of allowance issued (as of 09 Sept 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 31 Jul 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98676115
- Mark type
- Stylized text
- Filed
- 31 Jul 2024
- Published for opposition
- 15 Jul 2025
- Attorney of record
- Auma N. Reggy
Goods and services
- Class 035 — Advertising and business services: Business services provided across the healthcare industry, namely, managing logistics, supply chain management and financial records management in the field of cell and gene therapies; business advisory and consulting services provided across the healthcare industry relating to research and development of targeted therapies and diagnostics, clinical solutions, patient access, and technology products and services in the field of cell and gene therapies; providing public policy information in the field of cell and gene therapies
- Class 041 — Education and entertainment services: Educational services, namely, conducting seminars and programs in the field of cell and gene therapies and related topics and the distribution of educational and training material in connection therewith
Owner
- McKesson Plasma and Biologics LLC, Irving, TX, US
- McKesson Plasma and Biologics LLC, Irving, TX, US
Prosecution history
- 05 Mar 2026 — TEAS STATEMENT OF USE RECEIVED
- 09 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Jul 2025 — PUBLISHED FOR OPPOSITION
- 09 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 May 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 May 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 13 May 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 19 Feb 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 19 Feb 2025 — NON-FINAL ACTION E-MAILED
- 19 Feb 2025 — NON-FINAL ACTION WRITTEN
- 19 Feb 2025 — USE AMENDMENT ACCEPTED
- 18 Feb 2025 — ASSIGNED TO EXAMINER
- 17 Feb 2025 — AMENDMENT TO USE PROCESSING COMPLETE